[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342023-105":59,"doc-detail-342023-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","piperlongumine-in-combination-with-egfr-tyrosine-kinase-inhibitors-for-the-treatment-of-lung-cancer-cells","Piperlongumine in combination with EGFR tyrosine kinase inhibitors for the treatment of lung cancer cells","","EGFR tyrosine kinase inhibitor (EGFR-TKI) therapies such as erlotinib and gefitinib are approved for non-small cell lung cancer (NSCLC), but acquired resistance limits their effectiveness. Piperlongumine (PPL), an extract from long pepper fruit (Piper longum), has demonstrated anticancer activity. This study evaluates PPL alone and in combination with EGFR-TKIs (erlotinib, gefitinib) and cisplatin in H1299 and H1975 lung cancer cell lines, assessing viability, apoptosis, reactive oxygen species, and EGFR-mediated signaling.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/piperlongumine-in-combination-with-egfr-tyrosine-kinase-inhibitors-for-the-treatment-of-lung-cancer-cells/342023/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/piperlongumine-in-combination-with-egfr-tyrosine-kinase-inhibitors-for-the-treatment-of-lung-cancer-cells/342023.png","ImageObject",300,407,{"name":92,"@type":93},"Skyler","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",16,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What problem does the study address regarding EGFR-TKI treatment in NSCLC?","Question",{"text":113,"@type":114},"The study addresses acquired resistance that develops against EGFR-TKIs such as erlotinib and gefitinib, which can reduce their therapeutic effectiveness.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which cell lines and treatments were used to test piperlongumine?",{"text":118,"@type":114},"Piperlongumine, erlotinib, gefitinib, and cisplatin were tested alone and in combination in H1299 and H1975 lung cancer cell lines, with viability measured after 72 hours.",{"name":120,"@type":111,"acceptedAnswer":121},"How did the combinations of piperlongumine with EGFR-TKIs affect cancer cells?",{"text":122,"@type":114},"Combining piperlongumine with gefitinib or erlotinib produced significant reductions in cancer cell levels versus control, with apoptotic induction observed in both cell lines.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},342023,1790193865,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},2336464648746,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","ONCOLOGY RESEARCH 2024 32(11): 1709-1721 ARTICLE  \nPiperlongumine in combination with EGFR tyrosine kinase inhibitors for the treatment of lung cancer cells  \nSHAIL RAKESH MODI; TERRICK ANDEY*  \nDepartment of Pharmaceutical Sciences, Massachusetts College of Pharmacy and Health Sciences, Worcester, MA 01608, USA Key words: Piperlongumine (PPL), Non-small cell lung cancer (NSCLC), Tyrosine kinase inhibitors (TKI), Mutation, Resistance  \nAbstract: Objectives: EGFR tyrosine kinase inhibitor (EGFR-TKI) therapies such as erlotinib and geﬁtinib are approved for the treatment of non-small cell lung cancer (NSCLC) . However, the high incidence of acquired resistance to these EGFR-TKIs may preclude their effectiveness. Piperlongumine (PPL), an extract from the long pepper fruit (Piper longum), has been shown to possess anticancer properties. The purpose of the study was to investigate piperlongumine as an anticancer agent and to study a combination treatment approach with EGFR-TKIs against lung cancer cells. Methods: Anticancer efﬁcacy of PPL, erlotinib (ERL), geﬁtinib (GEF), and cisplatin (CIS) were investigated in H1299 and H1975 cell lines. Cells were treated with PPL, ERL, GEF, and CIS alone, and in combination, cell viability was determined after 72 h. The mechanism of PPL-induced cytotoxicity was investigated via reactive oxygen species (ROS) induction, and apoptosis induction using acridine orange/ethidium bromide staining and ﬂow cytometry. The effect of treatment on EGFR-mediated oncogenic signaling was investigated by immunoblotting for mitogenic and apoptotic markers. Results: PPL exhibited a potent cytotoxic effect in H1299 and H1975 cells compared to ERL, GEF, and CIS. Combination treatments of PPL with GEF and ERL showed signiﬁcant reductions in cancer cells compared to control in both cell lines, which were associated with apoptotic induction, but without signiﬁcant ROS induction. Compared to control, PPL with GEF signiﬁcantly increased apoptotic cell death in H1975as conﬁrmed with ﬂow cytometry. Treatment with PPL alone and in combination induced anti-mitogenic andapoptotic responses at the molecular level. Conclusion: PPL sensitized lung cancer cells to EGFR-TKI and induced  \npotent cytotoxic effects at low concentrations.  \nIntroduction  \nLung cancer is one of the leading causes of mortality worldwide with estimated deaths of approximately 125 thousand in the United States in 2024 [1] . One of the major lung cancer biomarkers is the epidermal growth factor receptor (EGFR) [2] . EGFR is a tyrosine kinase receptor present on the cell surface, which when activated leads to various downstream signaling, resulting in cell growth, cell proliferation, and cell survival. EGFR-tyrosine kinase inhibitors (EGFR-TKIs) such as erlotinib and geﬁtinib target tumors with overexpression of EGFR. These tyrosine kinase inhibitors bind reversibly to the adenosine triphosphate (ATP) binding site of the EGFR receptor, which blocks its  \n*Address correspondence to: Terrick Andey, [terrick.andey@mcphs.edu](terrick.andey@mcphs.edu)  \nReceived: 15 May 2024; Accepted: 09 August 2024;  \nPublished: 16 October 2024  \nactivation and downstream signaling [3,4] . These therapies are approved as ﬁrst-line treatment for metastatic non-small cell lung cancer (NSCLC) and are effective against cells harboring certain EGFR mutations, the so-called activating mutations such as L858R mutation. However, treatment of NSCLC patients with ﬁrst- and second-generation EGFRTKIs has been associated with acquired resistance due to the emergence of T790M-EGFR mutation. EGFR-T790M is a secondary point mutation on exon 20 that replaces methionine for threonine at the amino acid position 790 on the EGFR tyrosine kinase [5] and is present in more than half of NSCLC patients [6] . Consequently, the afﬁnity for the ATP increases and activates the downstream oncogenicand mitogenic signaling by the receptor [3,4] . On the other hand, activating mutations such as L858R–resulti","cbCaiqUZqOvWbMns","https://ap.wps.com/l/cbCaiqUZqOvWbMns","pdf",13803397,13,"English","# Abstract\n## Objectives, Methods, and Results\n## Conclusion and molecular rationale\n# Introduction\n## EGFR signaling and EGFR-TKIs in NSCLC\n## Acquired resistance mechanisms (e.g., T790M)\n## Role and prior biological activities of piperlongumine\n# Study Aims","[{\"question\":\"What problem does the study address regarding EGFR-TKI treatment in NSCLC?\",\"answer\":\"The study addresses acquired resistance that develops against EGFR-TKIs such as erlotinib and gefitinib, which can reduce their therapeutic effectiveness.\"},{\"question\":\"Which cell lines and treatments were used to test piperlongumine?\",\"answer\":\"Piperlongumine, erlotinib, gefitinib, and cisplatin were tested alone and in combination in H1299 and H1975 lung cancer cell lines, with viability measured after 72 hours.\"},{\"question\":\"How did the combinations of piperlongumine with EGFR-TKIs affect cancer cells?\",\"answer\":\"Combining piperlongumine with gefitinib or erlotinib produced significant reductions in cancer cell levels versus control, with apoptotic induction observed in both cell lines.\"}]","Piperlongumine in combination with EGFR tyrosine kinase inhibitors for the treatment of lung cancer cells | PDF",1790044800,33,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/74a22633e49ac921a831df4b4676ba18.webp",983,1390,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d47d5c2984044b9bedfeb542baa17520.webp",982,1388,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f4a6172240cfd81247716fc0b7908aff.webp",981,1387,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/60526e2bb870d3067a1bd0fec0b5db42.webp",980,1385]